IBI322 + azacitidine

**IBI322 + azacitidine** is an experimental combination therapy for higher-risk hematologic malignancies, particularly myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). IBI322 is a bispecific antibody targeting CD47 and PD-L1, designed to block the CD47 "don’t eat me" signal and the PD-L1 immune checkpoint, thereby promoting tumor cell phagocytosis and reversing tumor-mediated immune evasion. Azacitidine is a pyrimidine nucleoside analogue and DNA methyltransferase inhibitor; it has established utility in treating MDS and certain AML subtypes by promoting tumor cell death and restoring normal gene expression through DNA hypomethylation. Clinical studies are underway to evaluate the efficacy and safety of the combination, with the rationale that azacitidine's demethylating effects may further enhance the immunomodulatory and antitumor activity of IBI322.

Brand names

VidazaOnuregAzacitidine AccordAzacitidine BetapharmAzacitidine KabiAzacitidine Mylan

Other names

5-azacytidine